• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

    4/22/25 5:30:00 AM ET
    $LIPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LIPO alert in real time by email

    Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse

    Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts

    Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement

    PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10, for the treatment of oral lichen planus (OLP). The Company also recently reported full enrollment across all three planned dose cohorts.

    Treatment with LP-310 at the 0.50 mg dose demonstrated statistically significant improvements in multiple patient-reported and investigator-measured efficacy endpoints, reinforcing LP-310's potential as a non-steroidal, locally delivered therapy for OLP. The trial, currently active across seven U.S. study sites, has now progressed to the third and highest dose cohort (1.0 mg/10 mL), with topline results expected in the second quarter of 2025.

    "These results mark meaningful progress for LP-310 and further strengthen our confidence in its clinical and commercial potential," said Jonathan Kaufman, Co-Founder and Chief Executive Officer of Lipella Pharmaceuticals. "With the Phase 2a trial now fully enrolled and final data expected this quarter, we are advancing toward key value-driving milestones, including a Phase 2b IND submission and broader regulatory engagement to support the program's continued development."

    Topline Findings from the 0.50 mg Cohort:

    • Investigator Global Assessment (IGA): Improved from 3.42 ± 0.21 at baseline to 2.71 ± 0.30 at week 1 (p=0.029), 1.71 ± 0.43 at week 4 (p=0.007) and 2.75 ± 0.34 at week 6 (p=0.112).
    • Reticulation, Erythema and Ulceration (REU) Score: Reduced from 26.91 ± 2.54 at baseline to 17.02 ± 2.36 at week 1 (p=0.003), 11.88 ± 2.91 at week 4 (p=0.003) and 18.47 ± 4.12 at week 6 (p=0.028).
    • Oral Lichen Planus Symptom Severity Measure (OLPSSM): Decreased from 14.92 ± 2.10 at baseline to 9.87 ± 2.27 at week 1 (p=0.032), 4.88 ± 2.15 at week 4 (p=0.003) and 8.42 ± 3.98 at week 6 (p=0.028).
    • Pain Numerical Rating Scale (NRS): Improved from 6.42 ± 0.75 at baseline to 4.25 ± 0.89 at week 1 (p=0.003), 2.25 ± 1.09 at week 4 (p=0.003) and 3.52 ± 1.51 at week 6 (p=0.028).
    • Global Response Assessment (GRA): Significant improvement was observed at week 4 (p=0.028).

    Safety and Tolerability

    LP-310 continues to be well tolerated, with no treatment-related SAEs and no patient dropouts. All participants successfully adhered to the twice-daily 10-milliliter rinse regimen. Pharmacokinetic analysis confirmed that tacrolimus levels remained undetectable or minimal in all patients, reinforcing LP-310's ability to deliver localized benefits without systemic toxicity.

    "We're very encouraged by the positive data from the 0.50 mg cohort, which demonstrated statistically significant efficacy across multiple clinical measures while maintaining a strong safety profile," said Dr. Michael Chancellor, Co-Founder and Chief Medical Officer of Lipella Pharmaceuticals. "Oral lichen planus is a painful, chronic condition with no FDA-approved treatment and limited therapeutic options. The symptom relief reported by patients, along with reductions in inflammation and ulceration, highlights LP-310's potential to be a transformative, steroid-free, and easy-to-use therapy that addresses a longstanding clinical unmet need and improves quality of life."

    Next Steps in Development

    With enrollment now complete across all three dose cohorts, Lipella is positioned to deliver final topline data from the 1.0 mg cohort in Q2 2025. These data are expected to form the foundation for upcoming regulatory interactions and next-phase clinical advancement. Key development milestones include:

    • Reporting final phase 2a topline results in Q2 2025
    • Advancing discussions with regulatory agencies including submission of an Investigational New Drug (IND) application for a Phase 2b trial in late 2025
    • Preparing to pursue FDA Breakthrough Therapy designation request

    About LP-310

    LP-310 is an innovative oral rinse formulation of LP-10 (tacrolimus), developed to address OLP. Designed to provide localized therapeutic effects while minimizing systemic exposure, LP-310 offers a promising new approach to managing this painful and often debilitating condition.

    A Phase 2a multicenter, dose-ranging clinical trial is currently underway to evaluate the safety, tolerability and efficacy of LP-310 in adult participants with symptomatic OLP. The trial includes three dose levels (0.25 mg, 0.5 mg and 1.0 mg of tacrolimus) and is being conducted across seven active U.S. sites, which are now recruiting participants. Lipella has reported topline data from the first two cohorts (0.25 mg and 0.50 mg), with the final cohort (1.0 mg) currently enrolling. Topline results from the 1.0 mg cohort are expected in the first half of 2025.

    For more information about the study or to participate, visit https://lipella.com/oral-lichen-planus-treatment/ or https://clinicaltrials.gov/study/NCT06233591.

    About Lipella Pharmaceuticals Inc.

    Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn.

    Forward-Looking Statements

    This press release includes certain "forward-looking statements" which are not historical facts, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, the current clinical trial results for LP-310 and our other products general capital market risks, our ability to regain and maintain compliance with the listing standards of The Nasdaq Stock Market LLC, regional, national or global political, economic, business, competitive, market and regulatory conditions, our current liquidity position and the need to obtain additional financing to support ongoing operations, and other risks as more fully described in our filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax or investment advice and should consult with your own advisors as to the matters described herein, as applicable.

    CONTACT

    Jonathan Kaufman

    Chief Executive Officer

    Lipella Pharmaceuticals Inc.

    [email protected]

    1-412-894-1853

    PCG Advisory

    Jeff Ramson

    [email protected]



    Primary Logo

    Get the next $LIPO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LIPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LIPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      4/7/25 7:16:11 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/17/25 8:12:52 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Kaufman Jonathan H

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/11/25 8:01:27 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    SEC Filings

    See more
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/25/25 3:14:40 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/20/25 4:02:53 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - LIPELLA PHARMACEUTICALS INC. (0001347242) (Filer)

      6/16/25 4:25:47 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

      PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen

      6/25/25 3:15:00 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

      PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Spec

      6/20/25 3:19:25 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

      PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled "Systems and Methods of Detecting Interstitial Cystitis." The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enha

      6/17/25 8:30:00 AM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      5/15/24 4:39:19 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

      4 - LIPELLA PHARMACEUTICALS INC. (0001347242) (Issuer)

      3/19/24 6:21:08 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LIPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:09:22 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

      SC 13G/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      11/14/24 5:00:15 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

      SC 13D/A - LIPELLA PHARMACEUTICALS INC. (0001347242) (Subject)

      10/17/24 5:00:44 PM ET
      $LIPO
      Biotechnology: Pharmaceutical Preparations
      Health Care